Interstitial Granulomatous Dermatitis Associated With Darifenacin
September 2008 | Volume 7 | Issue 9 | Case Reports | 895 | Copyright © September 2008
Holly R. Mason MD PhD, Jil K. Swanson PA-C, Jonhan Ho MD, Timothy J. Patton DO
Abstract
Interstitial granulomatous dermatitis is most commonly associated with rheumatoid arthritis (RA) but may be induced by medications
as well. Darifenacin is a muscarinic antagonist which was FDA approved for the treatment of overactive bladder in December 2004.
The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.